Evidence map›Paper›PMID 20028806›Full record

ArticleInfection and immunity2010

Influence of mannan and glucan on complement activation and C3 binding by Candida albicans.

Gayle M Boxx, Thomas R Kozel, Casey T Nishiya, Mason X Zhang

Abstract read
In one paragraph

Article in Infection and immunity, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 29 citations in OpenAlex.

  1. Trial
  2. International journal of molecular sciences · 2021
    Article
  3. Recognition ofMicroorganisms · 2020
    Review
  4. Article
  5. Frontiers in immunology · 2020
    Review
  6. Mechanisms of PathogenicFrontiers in cellular and infection microbiology · 2020
    Review
  7. The Fungal Cell Wall:Frontiers in microbiology · 2019
    Review
  8. Article
  9. Article
  10. Immune Recognition of Fungal Polysaccharides.Journal of fungi (Basel, Switzerland) · 2017
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Gayle M BoxxDepartment of Biological Sciences, California State University-Long Beach, Long Beach, CA 90840, USA.
Thomas R Kozel
Casey T Nishiya
Mason X Zhang
California State University, Long Beach · USUniversity of Nevada, Reno · US

Funding

Yeast Endosome to Vacuole Mutants--Evaluation/CloningS06GM063119 · NIGMS · CALIFORNIA STATE UNIVERSITY LONG BEACH · PI KINGSFORD, LAURA · 2001 to 2008
$12.1M
PHOSPHOMANNOPROTEIN ADHESIN AS A VACCINE CANDIDATEP01AI037194 · NIAID · LA BIOMED RES INST/ HARBOR UCLA MED CTR · PI EDWARDS, JOHN E. · 1995 to 2003
$3.6M
Cryptococcal polysaccharide-phagocytosis inhibitionR01AI014209 · NIAID · UNIVERSITY OF NEVADA RENO · PI KOZEL, THOMAS R · 1985 to 2009
$1.9M
CRYPTOCOCCAL POLYSACCHARIDE--PHAGOCYTOSIS INHIBITIONR37AI014209 · NIAID · UNIVERSITY OF NEVADA RENO · PI KOZEL, THOMAS R · 1995 to 2004
$1.5M
REGULATION OF COMPLEMENT ACTIVATION BY CANDIDA ALBICANSR01AI044786 · NIAID · UNIVERSITY OF NEVADA RENO · PI KOZEL, THOMAS R · 2000 to 2004
$1.2M
Isotype-dependent efficacy of human mAbs against CandidaR15AI052139 · NIAID · CALIFORNIA STATE UNIVERSITY LONG BEACH · PI ZHANG, MASON X · 2002 to 2002
$143k
NIAID NIH HHS AI014209NIAID NIH HHS AI037194NIAID NIH HHS AI044786NIAID NIH HHS AI052139NIAID NIH HHS P01 AI037194NIAID NIH HHS R01 AI014209NIAID NIH HHS R01 AI044786NIAID NIH HHS R15 AI052139NIAID NIH HHS R37 AI014209NIGMS NIH HHS GM063119NIGMS NIH HHS S06 GM063119
6 · The paper itself

Abstract

The complement system is important for host resistance to hematogenously disseminated candidiasis. However, modulation of complement activation by cell wall components of Candida albicans has not been characterized. Although intact yeast display mannan on the surface, glucan, typically located in the interior, becomes exposed during C. albicans infection. We show here the distinct effects of mannan and glucan on complement activation and opsonophagocytosis. Previous studies showed that intact cells are resistant to initiation of complement activation through the alternative pathway, and antimannan antibody reverses this resistance via an Fc-independent mechanism. The present study shows that this mannan-dependent resistance can be overcome by periodate-borohydride conversion of mannose polysaccharides to polyalcohols; cells treated with periodate-borohydride initiate the alternative pathway without the need for antibody. These observations identify an inhibitory role for intact mannan in complement activation. Next, removal of the surface-displayed mannan by acid treatment of periodate-borohydride cells exposes glucan. Glucan-displaying cells or purified beta-glucan initiate the alternative pathway when incubated with the purified proteins of the alternative pathway alone, suggesting that C. albicans glucan is a natural activator of the alternative pathway. Finally, ingestion of mannan-displaying cells by human neutrophils requires anti-mannan antibody, whereas ingestion of glucan-displaying cells requires complement. These results demonstrate a contrasting requirement of natural antibody and complement for opsonophagocytosis of C. albicans cells displaying mannan or glucan. Thus, differential surface expression of mannan and glucan may influence recognition of C. albicans by the complement system.

Indexed as

Candida albicansComplement ActivationComplement C3Complement Pathway, AlternativeGlucansHumansImmunologic FactorsMannansNeutrophilsOpsonin ProteinsPhagocytosisProtein BindingC3 protein, humanComplement C3GlucansImmunologic FactorsMannansOpsonin Proteins

Identifiers

PMID20028806
PMCPMC2825936
OpenAlexW2136790131

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.